• Molecular NameParamethadione
  • SynonymNA
  • Weight157.169
  • Drugbank_IDDB00617
  • ACS_NO115-67-3
  • Show 3D model
  • LogP (experiment)0.763
  • LogP (predicted, AB/LogP v2.0)0.32
  • pkaN/A
  • LogD (pH=7, predicted)0.32
  • Solubility (experiment)8.4 mg/mL
  • LogS (predicted, ACD/Labs)(ph=7)-0.92
  • LogSw (predicted, AB/LogsW2.0)58.42
  • Sw (mg/ml) (predicted, ACD/Labs)18.91
  • No.of HBond Donors0
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds1
  • TPSA46.61
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.
  • Absorption_valueN/A
  • Absorption (description)Rapid via the digestive tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPrimarily hepatic (mainly via cytochrome P450 isozyme 2C9), paramethadione is completely demethylated to 5-ethyl-5-methyl-2,4-oxazolidinedione, the active metabolite.
  • Half lifeparamethadione about 16 h after a single dose, N-desmethylparamethadione about 7 to 14 days during chronic administration.
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include clumsiness or unsteadiness, coma, severe dizziness, severe drowsiness, severe nausea, and problems with vision.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A